Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 233

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes

Open access
Hodgson, Darren R., Dougherty, Brian A., Lai, Zhongwu, Fielding, Anitra, Grinsted, Lynda, Spencer, Stuart, O’Connor, Mark J., Ho, Tony W., Robertson, Jane D., Lanchbury, Jerry S., Timms, Kirsten M., Gutin, Alexander, Orr, Maria, Jones, Helen, Gilks, Blake, Womack, Chris, Gourley, Charlie, Ledermann, Jonathan, Barrett, J. Carl·2018·British Journal of Cancer

Abstract

Olaparib (Lynparza™) is a PARP inhibitor approved for advanced BRCA -mutated ( BRCA m) ovarian cancer. PARP inhibitors may benefit patients whose tumours are dysfunctional in DNA repair mechanisms unrelated to BRCA1/2 . We report exploratory analyses, including the long-term outcome of candidate biomarkers of sensitivity to olaparib in BRCA wild-type ( BRCA wt) tumours. Tumour samples from an olaparib maintenance monotherapy trial (Study 19, D0810C00019; NCT00753545) were analysed. Analyses included classification of mutations in genes involved in homologous recombination repair (HRR), BRCA1 promoter methylation status, measurement of BRCA1 protein and Myriad HRD score. Patients with BRCA m tumours gained most benefit from olaparib; a similar treatment benefit was also observed in 21/95 patients whose tumours were BRCA wt but had loss-of-function HRR mutations compared to patients with no detectable HRR mutations (58/95). A higher median Myriad MyChoice ® HRD score was observed in BRCA m and BRCA wt tumours with BRCA1 methylation. Patients without BRCA m tumours derived benefit from olaparib treatment vs placebo although to a lesser extent than BRCA m patients. Ovarian cancer patients with tumours harbouring loss-of-function mutations in HRR genes other than BRCA1 / 2 may constitute a small, molecularly identifiable and clinically relevant population who derive treatment benefit from olaparib similar to patients with BRCA m.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41416-018-0274-8

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 233

Metadata

Authors
Hodgson, D. R., Dougherty, B. A., Lai, Z., Fielding, A., Grinsted, L., Spencer, S., O’Connor, M. J., Ho, T. W., Robertson, J. D., Lanchbury, J. S., Timms, K. M., Gutin, A., Orr, M., Jones, H., Gilks, B., Womack, C., Gourley, C., Ledermann, J., & Barrett, J. C.
Venue
British Journal of Cancer
Published
2018-10-24
Volume
119
Issue
11
Pages
1401-1409
ISSN
  • 0007-0920 (ISSN-L)
  • 1532-1827
OpenAlex
W2896626889
Cited by
233
References
7
FWCI
8.00
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes. https://app.cochat.ai/papers/10.1038/s41416-018-0274-8
The paper
Hodgson, D. R., Dougherty, B. A., Lai, Z., Fielding, A., Grinsted, L., Spencer, S., O’Connor, M. J., Ho, T. W., Robertson, J. D., Lanchbury, J. S., Timms, K. M., Gutin, A., Orr, M., Jones, H., Gilks, B., Womack, C., Gourley, C., Ledermann, J., & Barrett, J. C. (2018). Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes. British Journal of Cancer. https://doi.org/10.1038/s41416-018-0274-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.